Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2003

View Archived Issues

LY-510929 characterized in animal models as a treatment for type 2 diabetes and dyslipidemia

Preclinical activity of LM-4156, a balanced activator of PPARalpha and PPARgamma

11-Beta-HSD1 inhibitors presented by Biovitrum researchers

Dompe patents novel inhibitors of IL-8 and GROalpha-induced chemotaxis

New aP2 or dual aP2/k-FABP inhibitors and their use disclosed by BMS scientists

Novel factor Xa inhibitors in early development at GSK

Bayer claims the preparation and use of synthetic andrimide and moiramide B analogues

Neurogen patents covers new GABA-A receptor ligands

ORL1 receptor agonists and their use as antitussives, analgesics, anxiolytics, etc.

Preclinical data on ISIS-113715, a PTP1B antisense oligonucleotide for the treatment of diabetes

OSI recovers North American rights to market Gelclair for oncology

Extended-release alfuzosin approved for BPH

New phase II study evaluates Dacogen in combination with Gleevec for CML

Inhibition of p38 MAP kinase effective for prevention and treatment of diabetes in NOD mice

Xyotax granted fast track status for advanced NSCLC

Zavesca approved in Israel for Gaucher's disease

Adventrx chosen as new corporate identity for Biokeys

Bile acid sequestrant from BTG, ready for phase III trials, available for licensing

Vaxim discovers SARS antigenic peptide

Health-related quality-of-life results from phase III Riquent trial

Cardiovascular agent offered for licensing by Biorex

EN-101 enters extension study for myasthenia gravis

Clinical hold on Enzo Biochem's HIV gene therapy trials lifted

NS-2330 enters further phase II study in Parkinson's disease

Trisenox NDA submitted in Japan

Pipeline update at Celltech Group

Preclinical antitumor activity of AP-23573 characterized at ASCO meeting

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...